New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
07:32 EDTLGNDLigand says Phase 3 PETIT2 study met primary endpoint
Ligand Pharmaceuticals (LGND) announces that its partner, GlaxoSmithKline (GSK), presented the results from the Phase 3 PETIT2 study evaluating the efficacy of eltrombopag vs. placebo in pediatric patients with chronic immune thrombocytopenic purpura. Eltrombopag - marketed as Promacta in the U.S. and as Revolade in Europe and other countries across the world - met its primary endpoint, achieving a statistically significant improvement in platelet counts with almost 40% of patients treated with eltrombopag attaining a consistent platelet response for 6 of 8 weeks compared to placebo. The PETIT2 study results were highlighted today as part of a Press Briefing and Oral Presentation at the European Hematology Association Annual Congress in Milan, Italy. GSK also announced that it is moving forward with planned regulatory submissions for a pediatric indication in cITP later this year. Efficacy results for PETIT2 were consistent across age cohorts. The safety profile was consistent with the established profile for eltrombopag and no new safety concerns were observed. The most common adverse events occurring most frequently in the eltrombopag arm included nasopharyngitis, rhinitis, cough and respiratory tract infection. Grade 3/4 AEs occurred in 12.7% of patients treated with eltrombopag and 10.3% of patients in the placebo group. Serious AEs were reported in 8% of eltrombopag-treated patients vs. 14% in the placebo arm. Additional results from an early phase study of eltrombopag in previously treated pediatric patients with cITP were also presented at the European Hematology Association Annual Congress.
News For LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
10:01 EDTLGNDOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Bacterin (BONE) initiated with a Buy at H.C. Wainwright... Cognizant (CTSH) initiated with a Buy at Argus... Comerica (CMA) initiated with a Neutral at UBS... Delphi Automotive (DLPH) initiated with a Neutral at Northcoast... Dunkin' Brands (DNKN) initiated with a Neutral at UBS... Easterly Government Properties (DEA) initiated with an Outperform at RBC Capital... Fifth Third (FITB) initiated with a Buy at UBS... Hilton (HLT) initiated with an Outperform at RBC Capital... KeyCorp (KEY) initiated with a Neutral at UBS... Ligand (LGND) initiated with a Buy at CRT Capital... M&T Bank (MTB) initiated with a Neutral at UBS... MPLX (MPLX) initiated with a Hold at Evercore ISI... Marriott (MAR) initiated with an Outperform at RBC Capital... Nexvet Biopharma (NVET) initiated with an Outperform at JMP Securities... Regions Financial (RF) initiated with a Neutral at UBS... Shell Midstream (SHLX) initiated with a Buy at Evercore ISI... Starwood (HOT) initiated with a Sector Perform at RBC Capital... Sunoco Logistics (SXL) initiated with a Hold at Evercore ISI... Syneron Medical (ELOS) initiated with a Buy at Brean Capital... Tesoro Logistics (TLLP) initiated with a Buy at Evercore ISI... Valero Energy Partners (VLP) initiated with a Buy at Evercore ISI... Vista Outdoor (VSTO) initiated with a Buy at CRT Capital... Zions Bancorp (ZION) initiated with a Sell at UBS.
08:23 EDTLGNDLigand initiated with a Buy at CRT Capital
Target $102.
March 2, 2015
09:19 EDTLGNDLigand data should establish superiority of Kyprolis, says Roth Capital
Subscribe for More Information
February 19, 2015
14:52 EDTLGNDLigand management to meet with Craig-Hallum
Meetings to be held in Minneapolis on February 23 and in Chicago on February 24 hosted by Craig-Hallum.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use